Genes implicated in multiple sclerosis pathogenesis from

consilience of genotyping and expression profiles in relapse and remission by Arthur, AT et al.
BioMed CentralBMC Medical Genetics
ssOpen AcceResearch article
Genes implicated in multiple sclerosis pathogenesis from 
consilience of genotyping and expression profiles in relapse and 
remission
Ariel T Arthur*1, Patricia J Armati1, Chris Bye3, Southern MS Genetics 
Consortium4, Robert NS Heard2, Graeme J Stewart2, John D Pollard1 and 
David R Booth2
Address: 1Department of Medicine and the Nerve Research Foundation, the University of Sydney, Sydney, Australia, 2Institute for Immunology 
and Allergy Research, Westmead Millennium Institute, Sydney, Australia, 3Westmead Millenium Institute, Sydney, Australia and 4The University 
of Melbourne, Melbourne, Australia
Email: Ariel T Arthur* - ariela@med.usyd.edu.au; Patricia J Armati - armati55@med.usyd.edu.au; Chris Bye - cbye@hfi.unimelb.edu.au; 
Southern MS Genetics Consortium - rubio@hfi.unimelb.edu.au; Robert NS Heard - heard@idx.com.au; 
Graeme J Stewart - stewartg@westgate.wh.usyd.edu.au; John D Pollard - jdpoll@med.usyd.edu.au; 
David R Booth - davidb@westgate.wh.usyd.edu.au
* Corresponding author    
Abstract
Background: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous
system (CNS). Although the pathogenesis of MS remains unknown, it is widely regarded as an autoimmune
disease mediated by T-lymphocytes directed against myelin proteins and/or other oligodendrocyte
epitopes.
Methods: In this study we investigated the gene expression profiles of peripheral blood cells from patients
with RRMS during the relapse and the remission phases utilizing gene microarray technology. Dysregulated
genes encoded in regions associated with MS susceptibility from genomic screens or previous
trancriptomic studies were identified. The proximal promoter region polymorphisms of two genes were
tested for association with disease and expression level.
Results: Distinct sets of dysregulated genes during the relapse and remission phases were identified
including genes involved in apoptosis and inflammation. Three of these dysregulated genes have been
previously implicated with MS susceptibility in genomic screens: TGFβ1, CD58 and DBC1. TGFβ1 has one
common SNP in the proximal promoter: -508 T>C (rs1800469). Genotyping two Australian trio sets
(total 620 families) found a trend for over-transmission of the T allele in MS in females (p < 0.13).
Upregulation of CD58 and DBC1 in remission is consistent with their putative roles in promoting
regulatory T cells and reducing cell proliferation, respectively. A fourth gene, ALOX5, is consistently found
over-expressed in MS. Two common genetic variants were confirmed in the ALOX5 putatve promoter: -
557 T>C (rs12762303) and a 6 bp tandem repeat polymorphism (GGGCGG) between position -147 and
-176; but no evidence for transmission distortion found.
Conclusion: The dysregulation of these genes tags their metabolic pathways for further investigation for
potential therapeutic intervention.
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MS the most common cause of chronic neurological disa-
bility in young adults with a lifetime risk of one in 400 in
northern Europeans [1]. Most patients have the relapsing-
remitting (RR) form of MS characterised by episodes of
neurologic impairment followed by complete or almost
complete recovery [2]. A relapse is thought to be caused by
some trigger of the immune system resulting in the traf-
ficking of activated, myelin-reactive T-cells into the CNS
through a disrupted blood brain barrier (BBB) causing
acute inflammation. Early clinical symptoms result from
oligodendrocytic damage and/or demyelination. The
regression of symptoms is attributed to resolution of
immune-based attack and associated oedema and to par-
tial remyelination or redistribution of sodium channels
along demyelinated segments of axons [3]. Relapses may
be mild or severe with exacerbations lasting several days
to several weeks, or even months.
We aimed to investigate the gene expression profiles of
whole blood from RRMS patients during the relapse and
the remission phases utilizing gene microarrays and RT-
PCR for confirmation of results. Whilst obtaining RNA
samples for microarray analysis from brain tissue is prob-
lematic, peripheral blood is an appropriate tissue to study
since it is the trafficking compartment of cells of the
immune system and provides insight into the specific
components that may be driving the immune response,
contributing to both the disease and its exacerbations in
RRMS. We used this transcriptomic information to find
dysregulated genes, and then combined this with genetic
association data linking genomic regions with MS, to find
dysregulated genes encoded in genomic regions associ-
ated with MS. Since genomic studies have confirmed that
genes are often regulated by their 5' untranslated regions
[4,5], we then sought polymorphisms in these regions
and tested them for association with MS.
We used four key approaches in our study. First, since
demyelination is probably due largely to leukocytes in the
peripheral circulation, and much of the variation in leu-
kocyte expression is genetically controlled; we investi-
gated the mRNA profiles of peripheral blood cells using
whole blood rather than just mononuclear cells. Sec-
ondly, since many mRNA species are short-lived and sub-
ject to nucleases, blood was collected directly into a
solution which immediately halts transcription and
mRNA degradation. Thirdly, we recruited patients in
remission who were not receiving immunomodulatory
treatments and who had experienced 1–2 relapses within
2 years prior to blood sampling to ensure a patient cohort
with a similar disease course and severity. Patients under-
going relapse were sampled on admission to hospital and
prior to receiving any steroid treatment for their relapse.
Finally, because aberrant gene expression may be an effect
of MS rather than a cause, we investigated genetic differ-
ences in gene promoter regions, which would suggest
inherited factors as a cause for the gene dysregulation.
Studies on gene expression signatures in MS from cells
have indicated upregulation of pro-inflammatory, anti-
apoptotic pathways [6]. Earlier, we found evidence of dif-
ferences in gene expression between the progressive forms
of the disease, primary progressive (PPMS) and secondary
progressive MS [7], and by using the transcriptomic/
genomic approach identified a CD127 haplotype associ-
ated with PPMS. The association of this gene with MS has
now been widely replicated [8-10]. Here we use the same
approach, and so identify TGFβ1, CD58 and DBC1 as
implicated in MS pathogenesis. These and other identified
dysregulated genes suggest the involvement of genes regu-
lating the immune system and apoptosis in MS. Further,
one gene in particular, ALOX5, is upregulated in previous
studies [7,11], and in both our relapse and remission
cohorts.
Methods
Patient and control blood samples
Gene expression
Blood samples from RRMS patients were collected at the
MS Society Australia Clinic, or upon admittance to the
Institute of Clinical Neuroscience, at Royal Prince Alfred
Hospital, Sydney, NSW Australia. All patients recruited for
this study were assessed independently by a neurologist
who diagnosed a clinical relapse, in the case of the relaps-
ing cohort, or confirmed clinical remission of the patients
in the remission cohort. Blood samples were taken from
relapsing patients prior to immunomodulatory treatment,
whilst patients in remission were not receiving treatment
and had experienced 1–2 relapses in the 2 years prior to
blood sampling. Relapsing patients were between 30–66
years of age with a male to female ratio of 5:5, remission
patients were between 30–55 years of age with a male to
female ratio of 4:6. Control human blood samples were
obtained from staff at Westmead Hospital, NSW Australia.
The control individuals were Caucasian and between 20–
55 years of age with a male to female ratio of 5:20. Female
control RNA samples were pooled to obtain a single con-
trol sample. All blood samples (15 mls total) were numer-
ically coded and obtained after informed consent
according to the University of Sydney Human Ethics (pro-
tocol number 02/03/17) and the Central Sydney Area
Health Service (CSAHS) Ethics (protocol number X02-
0328).
DNA sequencing
Genomic DNA pools used for promoter region sequenc-
ing were constructed by the Institute for Immunology and
Allergy Research. Genomic DNA samples from 217 HLA-
DR2 positive MS patients, 155 HLA-DR2 negative MSPage 2 of 12
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from 187 unrelated healthy controls were pooled sepa-
rately using the Ban et al protocol [12], based on previ-
ously described methods [13].
Genotyping
Trio families (MS patient, mother and father) used for
genotyping were recruited by the Institute for Imunology
and Allergy Research.
RNA extraction
All whole blood samples were collected under standard
phlebotomy protocol into PAXgene tubes (PreAnalytix,
Switzerland) and RNA extracted from the samples using
the PAXgene Blood RNA Kit (PreAnalytix, Switzerland).
All methods followed the protocols supplied in the kit
[14].
RNA preparation for microarray analysis
The MessageAmp II Kit [15] was used to amplify the RNA
for use with 10.5 K Peter MacCallum microarrays. These
comprise ~10,500 elements representing 9,381 unique
cDNAs (Unigene Build 144) and were printed onto
superamine slides (Telechem) using a robotic arrayer
(Virtek) by The Peter MacCallum Cancer Institute, Aus-
tralia – full gene list published on the author's website
[16]. The SuperScript Indirect cDNA Labelling System
(Invitrogen) was used for cDNA production and CyDye
(Amersham Biosciences) labeling. The protocol supplied
was followed [17]. The labeled cDNA was hybridized at
65°C overnight, the arrays were washed and scanned
using a 4000B scanner (AXON Instruments), then visual-
ized using GenePix Pro 5.0 software. Each microarray was
repeated using alternate CyDye combinations so that
there were 2 arrays per patient. Each MS sample was com-
pared to the female reference (pool of 20 females). Male
controls were compared to this same reference. Genes dif-
ferent between the male controls and female reference
were considered 'sex-specific' and excluded from the anal-
ysis of MS samples versus the reference sample.
Microarray data analysis
Raw data files generated by the GenePix Pro software were
loaded into the program R [18] and normalized using the
freely available microarray analysis package Limma [18].
The data was normalized using the print-tip loess method
and all spots with an intensity value less than 100 were fil-
tered out of the data sets as these were considered unreli-
able. To avoid type 2 errors (false rejection of association)
we used the Significance Analysis of Microarrays (SAM)
package [19], which uses modified t tests to compare
results for each gene and uses an iterative procedure to
evaluate the likelihood of the association occurring by
chance. The SAM package was used in conjunction with
Limma to identify the most statistically significant dysreg-
ulated genes. The GOstat program [20] was used to iden-
tify gene ontology groups which were highly represented
in the dysregulated gene sets.
Quantitative real-time PCR
All primers were designed using Primer3 [21]. ALOX5
(H51574) forward primer sequence: 5'-CCACGGGGAC-
TACATCGAGTT-3' and reverse primer sequence: 5'-CTT-
TACGTCGGTGTTGCTTGAG-3'. TGFβ1 (R36467) forward
primer sequence: 5'-CGAGCCTGAGGCCGACTACTA-3'
and reverse primer sequence: 5'-CTCGGAGCTCTGATGT-
GTTGAA-3'.
All RNA samples were quantified using RiboGreen reagent
(Molecular Probes, Eugene, OR, USA) and fluorescence
measured using a FluoroCount fluorescence microplate
reader (Packard Bioscience, Meriden, CT, USA). Patient
and control pool RNA was reverse-transcribed into cDNA
by preparing 20 µl reverse transcription reaction contain-
ing: 500 ng RNA, 250 µg Oligo dT (Promega, Madison,
WI, USA), 10 mM dNTPs (Promega, Madison, WI, USA).
The reaction was incubated at 65°C for 5 min and cooled
on ice, then 5× buffer (Promega, Madison, WI, USA), 40
U RNase inhibitor (Promega, Madison, WI, USA), and
400 U reverse transcriptase (Promega, Madison, WI, USA)
was added and the reaction incubated at 42°C for 60 min
then 80°C for 15 min.
SYBR Green (Applied Biosystems Foster City, CA, USA)
was used to quantify cDNA by real-time PCR. The PCR
reaction contained cDNA derived from 5 ng of MS or con-
trol total RNA, SYBR Green master mix (Applied Biosys-
tems Foster City, CA, USA), and 100 ng of each primer.
The reaction was amplified in a Corbett Rotor-Gene 2000
real-time PCR cycler (Corbett Research, NSW, Australia)
using the following cycling profile: 1 cycle of 95°C for 10
min; 5 cycles (95°C for 30s, 64°C for 30s, 72°C for 30s);
35 cycles (95°C for 30s, 60°C for 30s, 72°C for 30s); then
72°C for 5 min. Melt curve analysis was then performed
between 75–99°C in 1°C increments. RT-PCR products
were electrophoresed on 2% 1× TBE agarose gels, stained
with ethidium bromide (0.5 µg/ml) to visualize the prod-
uct. Normalization to total RNA, or the 2-∆Ct method [22]
was used to determine differences in expression between
the MS individuals and the control pool.
Promoter region sequencing
Genomic DNA pools consisting of DNA samples from
217 HLA-DR2 positive MS patients, 155 HLA-DR2 nega-
tive MS patients, 169 probands from MS multiplex fami-
lies, and from 187 unrelated healthy controls were used
for promoter region sequencing. PCR primers were
designed to amplify the 5' untranslated promoter region
(approximately 500 bp upstream of the 1st exon) using
Primer3 [20]. ALOX5 (H51574) forward primerPage 3 of 12
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primer sequence: 5'-GGCTGAGGTAGATGTAGTCGTCA-
3'. TGFβ1 (R36467) forward primer sequence: 5'-
GGGAGGTGCTCAGTAAAGG-3' and reverse primer
sequence: 5'-CTCGCTGTCTGGCTGCTC-3'. PCR reactions
were prepared using 2× PCR Mastermix (MBI Fermentas,
Vilinus, Lithuania), 100 ng of each PCR primer and 50 ng
of pooled DNA samples or 0.1–1 µg of control individual
genomic DNA. Reactions were amplified in the Mastercy-
cler thermocycler (Eppendorf AG, Hamburg, Germany)
using the following 64° -60°C "touchdown" temperature
profile: 1 cycle of 95°C for 2 min 30 s; then 5 cycles (95°C
for 30 s, 64°C for 30 s, 72°C for 30 s), then 30 cycles of
(95°C for 30 s, 60°C for 30 s, 72°C for 30 s); then 1 cycle
of 72°C for 5 min. For GC-rich sequences in the ALOX5
and TGFβ1 promoter regions, 5% DMSO and 0.02 U/µl
Phusion DNA polymerase (Finnzymes, Finland) was also
added to the reaction and a 62° -58°C "touchdown" tem-
perature profile with a 98°C denaturation temperature,
was used: 1 cycle of 98°C for 2 min 30 s; then 5 cycles
(98°C for 30 s, 62°C for 30 s, 72°C for 30 s), then 30
cycles of (98°C for 30 s, 58°C for 30 s, 72°C for 30 s);
then 1 cycle of 72°C for 5 min. PCR products were elec-
trophoresed on 2% 1 × TBE agarose gels, stained with
ethidium bromide (0.5 µg/ml) to visualize PCR products.
The PCR products were then purified using 1 µl Exo-SAP-
IT (exonuclease I/Shrimp alkaline phosphatase) (USB
Corporation, Cleveland, OH, USA) incubated at 37°C for
15 min followed by 80°C for 15 min.
Unidirectional DNA sequencing was performed using an
ABI Prism Big Dye terminator sequencing kit version 3.0
(Applied Biosystems, Foster City, CA, USA). PCR products
were either sequenced in the forward or reverse direction
using an internal primer. ALOX5 (H51574) reverse inter-
nal primer sequence: 5'-CATCTAGCGCCGCAGC-3'.
TGFβ1 (R36467) forward internal primer sequence: 5'-
CTCAGTAAAGGAGAGCAATTC-3'. Reactions were incu-
bated at 95°C for 5 min, followed by 25 cycles (95°C for
30 s, 50°C for 15 s and 60°C for 4 min). Reactions were
then electrophoresed on an ABI PRISM 3100 Genetic Ana-
lyzer (Applied Biosystems, Foster City, CA, USA) by the
Westmead Millenium Institute DNA Sequencing Facility.
DNA sequences were viewed using ABI Prism Editview
software (Applied Biosystems, Foster City, CA, USA).
Genotyping
Up to 388 trio families, recruited by the Institute for
Immunology and Allergy Research, were utilized for this
genotyping study. Since appropriate matching of controls
is essential to avoid false positive associations resulting
from population stratification or non-random mating,
genetically unrelated family members of the MS patients
are usually used as controls. However, confounding due
to hidden stratification can still occur. For this reason we
have used trio families in this study. When a patient and
both parents (a "trio family") are considered, the non-
transmitted parental alleles form the controls. In these trio
families association was tested using the transmission dis-
equilibrium test (TDT) [23].
One hundred and two trio families were genotyped for the
ALOX5 6 bp (GGGCGG) deletion. PCR primers were
designed to amplify the transcription factor binding
region, containing the repeated motif GGGCGG, using
Primer3 [21]. Forward primer: 5'-AGGTCCCGCCCAGTC-
3' and reverse: 5'GGTCTGGCTCCAGGCT-3'. PCR reac-
tions were prepared using 2× ImmoMix PCR Mastermix
(Bioline), 100 ng of each PCR primer, 0.25 µl of 100%
DMSO and 50 ng of DNA samples. Reactions were ampli-
fied in the Mastercycler thermocycler (Eppendorf AG,
Hamburg, Germany) using the following 68° -64°C
"touchdown" temperature profile: 1 cycle of 96°C for 10
min; then 5 cycles (96°C for 30 s, 68°C for 30 s, 72°C for
30 s), then 25 cycles of (96°C for 30 s, 64°C for 30 s,
72°C for 30 s); then 1 cycle of 72°C for 5 min. PCR prod-
ucts were electrophoresed on 15% acrylamide gels made
with: 40% acrylamide; 10× TBE buffer; ammonium per-
sulfate (100 mg/ml); TEMED; and H2O. The gels were
stained with ethidium bromide (0.5 µg/ml) to visualize
PCR products. Transmission disequilibrium tests (TDT)
were performed using the Haploview program [24].
Three hundred and eighty eight trio families were geno-
typed for the TGFβ1 -508 C>T SNP. Genotyping of the
TGFβ1 SNP was performed by the Australian Genome
Research Facility (AGRF) (Queensland, Australia). The
AGRF custom SNP genotyping service utilized the homog-
enous MassExtend (hME – single base extension) ana-
lysed on the Sequenom Autoflex Mass spectrometer and
the Samsung 24 pin nanodispensor. SNP assays were
designed by AGRF, PCR oligos were obtained and then
processed in multiplex format, following PCR, on a mass
spectrometer. The mass spectrometer allowed different
SNPs to be identified with a high level of sensitivity.
Transmission disequilibrium tests (TDT) were performed
as above. The same genotyping strategy was employed for
an independent cohort of 250 trios collected by Victorian
institutions [25].
Results
Gene expression in RRMS: microarray vs. RT-PCR
Relapse
The gene expression profile of 10 RRMS patients in clini-
cal relapse compared to the control sample identified 989
statistically significant (p ≤ 0.05) up-regulated genes. Of
particular interest, ALOX5 was up-regulated 2.58 (± 0.59)
fold (mean microarray fold change for each individual),
whilst the RT-PCR results showed a 3.41 (± 0.29) fold
increase (Figure 1). TGFβ1 was up-regulated by 1.97 (±Page 4 of 12
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(± 0.24) according to RT-PCR (Figure 1). In addition, 536
statistically significant (p ≤ 0.05) genes were down-regu-
lated. The complete dysregulated gene list (obtained from
the limma analysis) for the relapse phase can be viewed
on the author's website [16].
Remission
The gene expression profile of 10 RRMS patients in remis-
sion compared to the control sample identified 655 statis-
tically significant (p ≤ 0.05) up-regulated genes. ALOX5
was also up-regulated during remission with a mean
microarray fold change of 1.84 (± 0.29) and 3.51 (± 0.36)
according to RT-PCR (Figure 1). According to the microar-
ray and RT-PCR analysis, TGFβ1 was not up-regulated in
RRMS patients during the remission phase. In addition,
662 statistically significant (p ≤ 0.05) genes were down-
regulated. The complete dysregulated gene list (obtained
from the limma analysis) for the remission phase can be
viewed on the author's website [16]. It should be noted
that due to the use of whole blood, fold change values of
significant differentially expressed genes were relatively
small, most around a value of 1.5–2.5.
GO pathways over-represented in the dysregulated gene 
sets
Table 1 lists the statistically significant (p ≤ 0.05) over-rep-
resented pathways, in the relapse and remission upregu-
lated gene sets, according to the GOstat program. There
were no over- or under-represented pathways in the
downregulated gene sets for either group. The over-repre-
sented pathways in the relapse upregulated gene set were
predominantly inflammation/apoptosis-related, whilst
the pathways in the remission upregulated gene set were
quite distinct, being related instead to protein transport
and localization.
Screening dysregulated genes for genomic association with 
MS
Prior to 2007, the two largest genomic screens have been
that of the GAMES collaborative using > 4000 microsatel-
lite markers in a case controls study [26], and the affected
family study using 400 SNPs in 1000 individuals [27]. The
latter identified 5q33, 17q23 and 19p13 as having the
highest LOD scores of the non-HLA region, and several
genes from the most dysregulated set in relapse and remis-
sion were encoded in these genomic regions (Table 2).
The meta-analysis from the GAMES study found 3 micro-
satellite markers associated with MS, D11S1986,
D19S552, and D20S894. Only 3 genes were encoded
within 1 MB, the likely maximum linkage distance, of any
of these markers: TGFβ1, CEACAM1 and the glial matura-
tion factor (all from 19q13.2). Only TGFβ1 is immune
cell specific [28], so this gene was selected for further
study. A more recent screen by the international multiple
sclerosis consortium (IMSGC), has provided a more com-
prehensive coverage of the genome [10], and identified 38
genes with primary evidence for association. Of these 4
were dysregulated in our study: CD58, DBC1, TAF1A, and
FHIT (Table 2). The genetic association of CD58 and
DBC1 were confirmed in the IMSGC's replication study.
Genotyping of the TGFβ1 promoter region
In the TGFβ1 promoter sequence, one known SNP at posi-
tion -508 T>C (rs1800469) was confirmed in both the MS
and control populations (Table 3). No other previously
identified or common novel SNPs were found. This SNP
was not associated with MS overall in the Westmead
cohort (380 trios), but as there was a trend (P < 0.13), and
the statistical power may not have been sufficient, we
increased the cohort size to 620 trios. However, in the
combined cohort there was still no significant association.
Genotyping of the ALOX5 promoter region
Because the gene association studies do not exclude
regions as having associations, we examined the promoter
region of ALOX5, which is upregulated in many MS
peripheral blood gene expression arrays [7,11], including
both the relapse and remission sets here. In the ALOX5
5'UTR sequence, one known SNP at position -557 T>C
(rs12762303) was confirmed in both the MS and control
populations, in addition to a deletion of one of the 6 bp
tandem repeats (GGGCGG) of the consensus Sp1 binding
sequence located between position -147 and -176
upstream from the ATG start site of the gene, as identified
by In et al [29] (Table 3). This region also contains 5 Egr-
1 binding motifs, located between position -148 and -
180.
Microarray vs RT-PCR results for ALOX5 and TGFβ1Figure 1
Microarray vs RT-PCR results for ALOX5 and 
TGFβ1. ALOX5 was up-regulated during relapse and remis-
sion while TGFβ1 was up-regulated only during the relapse 
phase.Page 5 of 12
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bp GGGCGG deletion, TDT testing showed no evidence
of transmission distortion for the deletion with 38 long
(normal sequence): 34 short (deletion) transmitted (p <
0.6). The short allele (minor allele) had a frequency of
0.19 in the MS population and 0.20 in the parental popu-
lation. This deletion appears therefore not to be a signifi-
cant risk factor in MS. We aimed to have the power to
detect at least a 1.5- to 2-fold risk; however, a larger sam-
ple would be required for statistical power to detect a
smaller risk factor. According to the McGinnis method, for
trios, a 1.5-fold risk requires 266 families for an 80%
chance of detecting association at a 5% significance level
whilst a 2-fold risk requires 85 families. Due to the small
sample size no stratification was performed. Both the -557
SNPs were equally represented in the control and MS
(DR+, DR-, Familial) pools, and so was not examined fur-
ther [30].
Table 1: GO pathways over-represented in the relapse and remission upregulated gene sets.
Disease Phase/Expression Gene Ontology p-value Genes
RELAPSE Upregulated GO:0009607 – Response to biotic 
stimulus
0.0462 GPR65, NMI, TAP2, IFI16, CSF2RB, TCRIM, ICOS, FCGR2B, 
CD48, BST1, TNFSF10, TLR5, MCP, DNAJB6, MNDA, GBP2, 
OXSR1, AQP9, TNFAIP6, NFIL3, CD53, GEM, LY96, DOCK2, 
IL1B, CLECSF6, PARP4, PLA2G7, CD97, MX2, 5233, HSPA1B, 
MAPK14, IL1R2, C3AR1, IFIT2, STAT1, IFNGR1, S100A8, EDEM1, 
LYZ, FAS, HSPA1L, LTBR, IL1RL1, B2M, HSPA1A
GO:0008219 – Cell death 0.0462 PARP4, GADD45B, MCL1, BCL2, GPR65, SMNDC1, RAF1, 
BIRC2, RAD21, CASP3, CASP10, TXNL1, BCLAF1, API5, STAT1, 
CUL1, YWHAG, TNFSF10, GADD45G, LYZ, FAS, IL1B, TRAF5, 
LTBR, TAX1BP1, CASP1, BID
GO:0006955 – Immune response 0.0462 GPR65, NMI, TAP2, IFI16, CSF2RB, TCRIM, ICOS, FCGR2B, 
BST1, TNFSF10, TLR5, MCP, MNDA, GBP2, AQP9, NFIL3, 
TNFAIP6, CD53, GEM, DOCK2, LY96, IL1B, CLECSF6, PARP4, 
PLA2G7, CD97, MX2, MAPK14, IL1R2, C3AR1, IFIT2, S100A8, 
FAS, LTBR, IL1RL1, B2M
GO:0016265 – Death 0.0462 PARP4, GADD45B, MCL1, BCL2, GPR65, SMNDC1, RAF1, 
BIRC2, RAD21, CASP3, CASP10, TXNL1, BCLAF1, API5, STAT1, 
CUL1, YWHAG, TNFSF10, GADD45G, LYZ, FAS, IL1B, TRAF5, 
LTBR, TAX1BP1, CASP1, BID
GO:0006952 – Defense response 0.0462 GPR65, NMI, TAP2, IFI16, CSF2RB, TCRIM, ICOS, FCGR2B, 
CD48, BST1, TNFSF10, TLR5, MCP, MNDA, GBP2, AQP9, NFIL3, 
TNFAIP6, CD53, GEM, DOCK2, LY96, IL1B, CLECSF6, PARP4, 
PLA2G7, CD97, MX2, MAPK14, IL1R2, C3AR1, IFIT2, S100A8, 
LYZ, FAS, LTBR, IL1RL1, B2M
GO:0004722 – Protein serine/
threonine phosphatase activity
0.0462 MTMR6, PPM1A, PPM1B, DUSP6, PPP2R2A, MTMR1
GO:0006915 – Apoptosis 0.0462 GADD45B, MCL1, BCL2, GPR65, SMNDC1, RAF1, BIRC2, 
RAD21, CASP3, CASP10, TXNL1, BCLAF1, API5, STAT1, 
YWHAG, CUL1, TNFSF10, GADD45G, FAS, IL1B, TRAF5, LTBR, 
TAX1BP1, CASP1, BID
GO:0012501 – Programmed cell 
death
0.0462 GADD45B, MCL1, BCL2, GPR65, SMNDC1, RAF1, BIRC2, 
RAD21, CASP3, CASP10, TXNL1, BCLAF1, API5, STAT1, 
YWHAG, CUL1, TNFSF10, GADD45G, FAS, IL1B, TRAF5, LTBR, 
TAX1BP1, CASP1, BID
GO:0005057 – Receptor signaling 
protein activity
0.0533 STAT1, TGFBR2, RAF1, LYN, ACVR1B, MAPK14, NSMAF, 
MAPK9, IRS1, TCRIM, IL1RL1, PDLIM5, MAPK8
REMISSION Upregulated GO:0015031- protein transport 0.0189 STXBP3, RANBP6, RAB2, PTTG1IP, ARF1, STX7, SNX2, GRP58, 
TLOC1, KPNB1, VDP, SNAG1, CLTC, COPB, TMED7, ARF3, 
RAB5A, TNPO1, RAB1A, COPA, RAB7, TLK1
GO:0045184 – establishment of 
protein localization
0.0189 STXBP3, RANBP6, RAB2, PTTG1IP, ARF1, STX7, SNX2, GRP58, 
TLOC1, KPNB1, VDP, SNAG1, CLTC, COPB, TMED7, ARF3, 
RAB5A, TNPO1, RAB1A, COPA, RAB7, TLK1
GO:0008104 – protein localization 0.0189 STXBP3, RANBP6, RAB2, PTTG1IP, ARF1, STX7, SNX2, GRP58, 
TLOC1, KPNB1, VDP, SNAG1, CLTC, COPB, TMED7, ARF3, 
RAB5A, TNPO1, RAB1A, COPA, RAB7, TLK1
GO:0005885 – Arp2/3 protein 
complex
0.046 ARPC2, ACTR3, ARPC3
GO:0030833 – regulation of actin 
filament polymerization
0.046 ARPC5, ARPC2, ARPC3Page 6 of 12
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Gene expression profiles of RRMS: relapse vs. remission
This study found a large number of dysregulated genes in
peripheral blood during the relapse and remission phases
of RRMS. When these sets of genes were compared against
the total gene set contained on the array, there was a sta-
tistically significant over-representation of apoptosis- and
inflammatory-related gene ontologies in the relapse up-
regulated gene set. This was expected as MS relapse is asso-
ciated with detrimental inflammation in which increases
in inflammatory cell activation and the activation of
inflammatory-related pathways is predominant. Recent
studies have also found upregulation of inflammatory
anti-apoptotic pathways in relapse [6], as a distinct MS
cluster [31], or in MS compared to controls [32-34]. This
is also consistent with the success of immunomodulatory
therapies in RRMS [35]. In the remission up-regulated
gene set, there was an over-representation of protein
transport and localization, and actin polymerisation
ontologies. Since these processes are altered when cells
change shape and motility, they may indicate that fluctu-
ation in cell trafficking is important in remission.
To date, microarray studies using MS blood have focused
on peripheral blood mononuclear cells. Recently, the
involvement of other blood cells in MS disease pathogen-
esis, such as neutrophils, has raised interest due to increas-
ing evidence suggesting that elements of the immune
response classically associated with allergy, may contrib-
ute to the pathogenesis of autoimmune CNS demyelinat-
ing diseases, such as MS and its animal model EAE [36].
We have identified the upregulation, both during relapse
and remission, of arachidonate 5-lipoxygenase (ALOX5),
an enzyme that catalyzes the initial steps in the conversion
of arachidonic acid to biologically active leukotrienes in
neutrophils [37,38]. Interestingly, we previously found an
up-regulation of ALOX5 in both secondary progressive
and primary progressive MS patients [7]. Gene expression
studies of MS and EAE lesions have also reported
increased levels of ALOX5 [11] in addition to other
allergy-related mediators [39-41].
Gene promoter variation and expression
Combining genomic and transcriptomic data has proved
useful in identifying genetic associations in disease. In this
way we earlier identified CD127 polymorphisms as asso-
ciated with PPMS [7], an association now independently
confirmed in two large cohorts [8,9]. The general princi-
pal of finding SNPs affecting expression in the 5' UTR
region has also now been established by combining
expression phenotype and HapMap data [4] or from the
ENCODE project [5]. We have examined the putative pro-
moter regions of TGFβ1 and ALOX5 for polymorphisms
then tested the association of these variants with MS. A
further advantage of this approach is that if promoter pol-
ymorphisms are associated with MS, then this provides
Table 2: Dysregulated genes from patients in relapse and remission encoded in genomic regions associated with MS.
Chromosomal Region Associated with 
MS
Genes Upregulated in Relapse Genes Downregulated in Relapse
5q331 SOX30 0
17q231 FTSJ3, USP32, MRC2, TLK2, PRKAR1A SMARCD2, HAN11WD
19p131 CD97, HOMER3, THRAP5, ILF3, OAZ1, AES, 
FUTC, SAFB, C19ORF6, ARHGEF18, SF4, 
GADD45B, CYP4F12
RGS19IP1, DHPS, MGC11271, KLF1, GCDH, 
FLJ90396, AZU1, FARSLA, KHSRP, TRIP10, 
ILVB1, ANGPTL4, NDUB7, NDUFA, 
MADCAM17
11q23 (D11S1986) 2 0 0
19q13.2 (D19S552) 2 TGFB1, CEACAM1, GMF 0
20p12 (D20S894) 2 0 0
IMSGC3 TAF1A FHIT, DBC1
Genes Upregulated in Remission Genes Downregulated in Remission
5q331 0 0
17q231 0 0
19p131 0 0
11q23 (D11S1986) 2 SDHD, CASP1, SIAT4C, APLP2 MGC2574, CD3E, RARRES3, CD3G, MTVR1, 
PCSK7
19q13.2 (D19S552) 2 CEACAM4, VASP PSG6, HNRPUL1, PVR, EIF3S12
20p12 (D20S894) 2 0 0
IMSGC3 CD58 FHIT
Chromosomal regions are those identified as associated by Sawcer et al (2005)1 [27] from the family study or by the GAMES collaboration (2006)2 
[26] using microsatellites (as marked) in a case/control study, and from the IMSGC SNP based genome wide analysis3 [10]. Genes are from the set 
of genes dysregulated in relapse and remission. Highlighted genes have been associated with MS in replication cohorts.Page 7 of 12
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Genomic regions chosen for screening of dysregulated
genes were based on the current largest genomic studies
[10,26,27]. The genomic region from the affected family
study was large, and this is reflected in the large number
of genes selected using these criteria. Three genes were tar-
geted from the more stringent criteria provided by the
GAMES study [26], and TGFβ1 was selected for further
study as it is the only one whose expression is confined to
immune cells.
Variations in the TGFβ1 promoter region
In addition to being close to the microsatellite in the
GAMES meta analysis [26], in 19q13.2, in which TGFβ1 is
encoded, this gene has been identified as being associated
with MS susceptibility in other studies [42-47]. Dysregu-
lated expression of TGFβ1 may have significant conse-
quences in MS pathogenesis and potentially could be due
to sequence variation in the TGFβ1 promoter region. Only
one common SNP, -508 T>C, was detected in the 500 bp
5' UTR putative promoter sequence [48] (Table 3). From
twin studies, Grainger et al [49] demonstrated TGFβ1
expression was under genetic control, and that the T allele
is associated with higher expression. Two groups have
studied the association of this SNP with MS [50,51]. We
found evidence for an association when 102 trios were
genotyped, and then increased the numbers to 388 trio
families. This is well in excess of the number needed to
have the statistical power to have an 80% chance of
detecting a risk factor of 1.5 at the 0.05 significance level
(212 families needed according to the McGinnis method).
We identified a trend towards over-transmission of the T
allele in MS in our patient cohort. We then tested the asso-
ciation in a second independent trio cohort, but found
only non-significant over-transmission (Table 4).
Interestingly Green et al, in contrast to Weinshenker et al,
found the wild-type C allele (or the "low-producer" geno-
type), which was under-transmitted in our study, was
associated with a milder disease course. EAE and human
drug response data suggest high TGFβ1 expression would
be protective [52-56]. Green et al [50] also found strong
linkage disequilibrium (LD) existing between the SNP at
position -508 and the codon 10 SNP and partial LD with
two other codon changing SNPs, which may result in an
altered function of the translated protein, which may in
turn be the cause of the association with susceptibility
found in our study. Neither Green et al (2001), nor Wein-
Table 3: Genetic variants in the putative ALOX5 and TGFβ1 promoters.
Gene GenBank Accession no. Common SNPs in the 5' upstream 
promoter region
SNPs found in this study
Arachidonate 5- Lipoxygenase 
(ALOX5)
H51574 rs12762303: -557 T>C (Hoshiko et al, 
1990)
-458 T>C (ensembl database)
Both identified in MS and control 
cohorts
GGGCGG tandem repeat deletion:
Between -146 and -176 (Hoshiko et 
al,1990)
Between -48 and -78 (ensembl 
database)
Transforming growth factor beta-1 
(TGFβ1)
R364674 rs12977628: -18 C>A (Kim et al, 1989)
+181 C>A (ensembl database)
rs1800469 identified in MS and 
control cohorts
rs17516265: -257 A>C (Kim et al, 
1989)
-59 A>C (ensembl database)
rs35318502: -315 C>T (Kim et al, 
1989)
-117 C>T (ensembl database)
rs35775330: -331 TT del (Kim et al, 
1989)
-133 TT del (ensembl database)
rs11466314: -448 G>A (Kim et al, 
1989)
-250 G>A (ensembl database)
rs1800469: -508 T>C (Kim et al, 1989)
-310 T>C (ensembl database)
Sequencing of the 5' upstream promoter region of pooled genomic DNA confirmed the presence of two common genetic variants in the ALOX5 
promoter: rs12762303 T>C and a 6 bp deletion of the tandem repeat sequence GGGCGG, in addition to a single common SNP in the TGFβ1 
promoter: rs1800469 T>C. Common SNPs and their positions in the 5' promoter region are shown according to nucleotide numbering in the 
ensembl database and by the authors who first described the promoter regions for ALOX5 (Hoshiko et al, 1990) [66] and TGFβ1 (Kim et al, 1989) 
[48]. Pooled DNA sequencing only detects common polymorphisms (> 10–15% of sample) [30].Page 8 of 12
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508 SNP and MS susceptibility (Table 5). A final assess-
ment of the significance of TGFβ1 as a risk factor will be
possible after larger, multiple cohorts have been studied,
with informed stratification for clinical parameters, and
after testing of epistatic interactions.
TGFβ1 is a multifunctional growth factor with demonstra-
ble immunosuppressive effects on a number of cells
including B cells, CD4+ T cells (Th1 and Th2), CD8+ cyto-
toxic T lymphocytes, natural killer cells and macrophages
[57] and has been recently been implicated as a key factor
in the differentiation of Th17 and T regulatory cells [58].
The full significance of TGFβ1-mediated effects on
immune responses is still incompletely understood, but
have been implicated in MS pathogenesis, with some
studies finding reduced TGFβ1 levels during a relapse and
an increase during remission [59-62]. However, it has also
been reported that TGFβ1 levels increase during remission
and even more so during relapse and in progressive
patients [63].
Variations in the ALOX5 promoter region
This study is the first to investigate the ALOX5 promoter
variations in MS patients. We did not identify any associ-
ation between the variant 5'UTR alleles and MS, suggest-
ing that these insertion/deletion (in/del) variants in the
Sp1/Egr-1 binding sites are not pathogenic in MS, and
may not be the cause of the increased ALOX5 expression
measured in MS patients by microarray analysis. How-
ever, extensive quantitative studies would be needed to
confirm this. As mentioned previously, our small sample
size does not exclude this in/del as an appreciable risk fac-
tor. It is possible that in MS, as found in asthma [64],
these promoter variations may affect disease modification
rather than disease susceptibility – an idea worthy of fur-
ther investigation if ALOX5 inhibitors were considered for
MS treatment.
IMSGC whole genome analysis: genes in the dysregulated 
set
Of the 38 genes implicated in MS susceptibility on the first
screen in the recently published whole genome screen,
four were in the dysregulated gene sets identified here
(Table 2). Two of these four genes were further supported
as associated with MS susceptibility in their replication
study: CD58 and DBC1. CD58, in common with the most
associated genes from that and other studies [8-10], IL7Rα
and IL2Rα, affects regulatory T cell (Treg) differentiation
and proliferation. TGFβ1 is essential for Treg differentia-
tion. The up-regulation of CD58 in remission is consistent
with the evidence that the protective allele is associated
with higher CD58 expression, and that CD58 promotes
Treg differentiation. Gene expression and genotyping data
therefore further implicate Tregs in MS pathogenesis.
Notably, the two most associated genes from the IMSGC
study, IL7Rα and IL2Rα, were not detected as dysregu-
lated in whole blood. DBC1 is anti-proliferative [65], so
that the higher expression observed in remission is con-
sistent with an immunosuppressive function.
Conclusion
We have reported the gene expression profiles of RRMS
during the relapse and remission phases, identifying
numerous dysregulated genes which may be specific to
RRMS pathogenesis. Up-regulation of ALOX5 during
relapse and remission and in progressive disease [7], sug-
gests a role for this molecule in MS. Higher expression of
ALOX5 in whole blood supports a possible role for neu-
trophils and allergic component in MS pathogenesis. A
pathogenic outcome of high expression could be
increased permeability of the blood brain barrier. No
association of ALOX5 promoter polymorphisms with MS
susceptibility was detected, but a much larger sample size
would be needed to exclude it as an appreciable risk fac-
tor.
The interpretation of the up-regulation of TGFβ1 and it
role in MS pathogenesis, is challenging. TGFβ1 has a mul-
titude of functions and there is evidence to support both
an immunosuppressive and a proinflammatory role for it
in MS pathogenesis. However, we propose that the
observed up-regulation of TGFβ1 during relapse may be in
response to the proinflammatory state and is acting to
promote Treg cell proliferation. This is consistent with the
observed increase in expression of CD58 in remission, a
gene now with strong support for association with MS.
Genotyping of the C>T SNP identified in the promoter
region of the TGFβ1 gene, revealed non-significant over-
transmission of the T allele in MS. Additional studies in
independent and larger cohorts stratified for these param-
eters are needed. Further study is appealing, as confirma-
tion of any genetic association and its phenotypic effect
Table 4: Genotyping of the TGFβ1 -508 T>C SNP (rs1800469) in 
423 informative MS trio families.
Group T:C P-value
Westmead 139T:115C 0.13
SMSGC 88T:81C ns
All (both cohorts) 227T:196C 0.13
IMSGC[10] C>T (1.1 odds ratio) 0.20
The samples were stratified and both corrected and uncorrected p-
values were calculated to avoid type I and type II errors. There is a 
trend for over-transmission of the T allele in MS (p < 0.13), and an 
association in females (puncorrected<0.04), HLA-DR+ (puncorrected<0.01), 
which was also found when data was combined from a second 
independent cohort (SMSGC), but was not significant after correction 
for multiple testing. However, the IMSGC transmission was in the 
reverse order, with C overtransmitted [10]. This was inferred from 
the transmission of rs2241714, which is in LD with rs1800469.Page 9 of 12
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apeutic interventions.
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